Page last updated: 2024-12-05

hydantoins

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10006
CHEBI ID27612
SCHEMBL ID27690
SCHEMBL ID9391323
MeSH IDM0010672

Synonyms (57)

Synonym
imidazole-2,4(3h,5h)-dione
CHEBI:27612 ,
2,4(3h,5h)-imidazoledione
NCI60_042041
einecs 207-313-3
2-imidazolin-4(or 5)-one, 2-hydroxy-
brn 0110598
nsc 9226
dantochlor
epa pesticide chemical code 128826
ccris 6532
imidazole-2,5h)-dione
nsc-9226
2,5h)-imidazoledione
nsc9226
2,4-imidazolidinedione
imidazolidine-2,4-dione
inchi=1/c3h4n2o2/c6-2-1-4-3(7)5-2/h1h2,(h2,4,5,6,7
C05146
glycolylurea
461-72-3
hydantoin ,
hydantoin, 98%
MLS001074863
smr000568395
H0167
AKOS000119723
NCGC00246990-01
hydantoins
hydantoine
unii-i6208298ta
i6208298ta ,
5-24-05-00188 (beilstein handbook reference)
A826996
BBL013200
STL164008
HMS2234P13
FT-0627104
HMS3373G13
hydantoin [mi]
hydantoin [who-dd]
2,4-(3h,5h)-imidazoledione
SCHEMBL27690
SCHEMBL9391323
DTXSID1052111
2,4-imidazolinedione
imidazolidine-2,4dione
Q-201207
mfcd00005259
F0001-1249
Z57131035
Q418082
CS-W011328
AS-10977
EN300-18068
D70295
bdbm50549804

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Also, body weight, skin and hair texture, and behavioural pattern (food and water intake and activity) did not reflect any toxic reaction in the host mice at this optimum dose."( Evaluation of toxicity of cypenhymustine, a new anticancer compound, in mice.
Bhattacharya, S; Das, H; Dutta, S; Ghosh, M; Sadhu, U; Sanyal, U, 1994
)
0.29
"3,4-Dihydroxyphenylacetaldehyde (DOPAL) is a toxic metabolite formed by the oxidative deamination of dopamine."( 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A, 2000
)
0.31
" Iprodione was more toxic than vinclozolin."( Cytotoxicity of the dicarboximide fungicides, vinclozolin and iprodione, in rat hepatoma-derived Fa32 cells.
Dierickx, PJ, 2004
)
0.32
" The present study was designed to explore the toxic effect of 1-methylhydantoin on renal proximal tubular cells in vitro."( 1-Methylhydantoin cytotoxicity on renal proximal tubular cells in vitro.
Jiang, YS; Li, CZ; Liu, D; Liu, FY; Peng, YM; Yang, B, 2007
)
0.34
" The objective of this study was to investigate the toxic effect of BCDMH on zebrafish."( Study of the toxicity of 1-Bromo-3-chloro-5,5-dimethylhydantoin to zebrafish.
Chen, C; Huang, M; Jin, H; Li, C; Li, W; Liu, C; Wang, A; Wei, J; Zhang, J, 2011
)
0.37
" Low oral rat LD50 values of 350 mg/kg and 759 mg/kg were predicted for cyclic isomers of iprodione, compared to that of the parent molecule (2776 mg/kg)."( Ultraviolet-vis degradation of iprodione and estimation of the acute toxicity of its photodegradation products.
Ballerini, L; Bouchonnet, S; Bourcier, S; Jellouli, H; Lassalle, Y; Nicol, É; Souissi, Y, 2014
)
0.4
" The incidence of adverse events was lower in the azimilide group."( Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
Bharucha, DB; Dorian, P; Kowey, PR; Mahaffey, KW; Robinson, VM, 2017
)
0.46
" Despite this limitation, azimilide showed promise as a safe and effective drug in reducing all-cause shocks, unplanned hospitalizations, and ED visits in ICD patients."( Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
Bharucha, DB; Dorian, P; Kowey, PR; Mahaffey, KW; Robinson, VM, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
"Anticonvulsant therapy was among the first areas to benefit from clinical pharmacokinetic studies."( Clinical pharmacokinetics of anticonvulsants.
Dam, M; Hvidberg, EF, 1976
)
0.26
" The l-form exhibited a longer plasma half-life (23."( Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethylhydantoin (Nirvanol) in the dog.
Bircher, J; Küpfer, A; Preisig, R, 1977
)
0.26
" Pharmacokinetic studies were undertaken to investigate these findings."( Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors.
Barker, R; Barratt, D; Brazzell, K; DuPriest, M; Griffin, B; Mayer, P; Park, YH; York, B, 1992
)
0.28
" After single doses of 20 to 50 mg, imirestat plasma concentrations declined with an apparent elimination half-life of 50 to 70 hr over the 168 hr in which levels were measured."( Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.
Brazzell, RK; Dobbs, R; Mayer, PR; McNamara, PJ; Slattery, JT; Teng, RL, 1991
)
0.28
" Plasma drug concentrations were measured by HPLC or liquid scintillation spectrometry and various pharmacokinetic parameters (clearance, CL; Vd, volume of distribution; and t1/2) were calculated from the data."( Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.
Barker, R; Brazzell, RK; Couch, R; McCue, B; Park, YH; Wooldridge, CB; York, B,
)
0.13
"A pediatric Phase I and pharmacokinetic study of the lipophilic alkylating agent spirohydantoin mustard (SHM) was conducted in 23 patients."( A pediatric phase I and pharmacokinetic study of spirohydantoin mustard.
Balis, F; Doherty, KM; Ettinger, LJ; Heideman, RL; Jeffries, SL; Kelley, JA; Packer, RJ; Poplack, DG; Reaman, GH; Roth, JS, 1988
)
0.27
"027 liters/min) and a 30- to 40-fold difference in elimination half-life (2."( Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
Aslanian, WS; Branch, RA; Jacqz, E; McAllister, CB; Wedlund, PJ; Wilkinson, GR, 1985
)
0.27
" The enantiomers had differing pharmacokinetic profiles, while the racemic compound exhibited pharmacokinetic parameters approximating the mean values of the individual enantiomers."( Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S).
Barker, R; DuPriest, M; Griffin, BW; Mayer, PR; Park, YH; Slattery, JT; Williams, GW; York, BM, 1993
)
0.29
" Body weight-adjusted Cmax did not differ between genders."( Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride.
Agnew, J; Bao, J; Bryson, P; Comer, P; Corey, A; Griffith, S; Li, J, 1997
)
0.3
" Unconfounded pharmacodynamic estimates required inclusion of circadian QTc variation in the pharmacodynamic model."( Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride.
Agnew, J; Brum, J; Corey, A; Parekh, N; Valentine, S; Williams, M, 1999
)
0.3
"2 L/kg (23%), and terminal exponential half-life = 78."( Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation.
Agnew, JR; Corey, AE; Nesbitt, JD; Powell, JH; Thompson, GA; Valentine, SN; Wagner, DL, 1999
)
0.3
"Pharmacokinetic (PK) and pharmacodynamic (PD) models for azimilide were developed and validated with sparse blood sampling and QTc interval data obtained during three clinical trials of azimilide for prevention of supraventricular arrhythmia recurrence."( A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide.
Agnew, JR; Grasela, TH; Ludwig, EA; Phillips, L; Thompson, GA, 2001
)
0.31
"Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior."( General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
Jusko, WJ; Mager, DE, 2001
)
0.31
" The pharmacokinetic and pharmacodynamic changes observed upon coadministration were small and are not expected to be clinically important."( Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin.
Agnew, JR; Corey, AE; Moehrke, W; Parekh, N; Powell, JH; Thompson, GA; Toothaker, RD; Valentine, SN, 2005
)
0.33
"The development of reliable relationships between in vivo target engagement, pharmacodynamic activity, and efficacy in chronic disease models is beneficial for enabling hypothesis-driven drug discovery and facilitating the development of patient-focused candidate selection criteria."( Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.
Adams, LA; Chambers, MG; Durham, TB; Lin, C; Liu, C; Marimuthu, J; Mitchell, PG; Mudra, DR; Swearingen, CA; Thirunavukkarasu, K; Toth, JL; Weller, JM; Wiley, MR, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" The absorption rate and fraction are very much dependent on the pharmaceutical preparation, and changes of brand may alter the plasma level of phenytoin in spite of unaltered dose."( Clinical pharmacokinetics of anticonvulsants.
Dam, M; Hvidberg, EF, 1976
)
0.26
" Bioavailability following topical dosing increased with dose, although not in a linear fashion."( Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration.
Brazzell, RK; Hackett, RB; McCue, BA; Wooldridge, CB, 1990
)
0.28
"Pharmacokinetics and bioavailability for the 1-benzenesulfonylhydantoin derivatives and 1-unsubstituted hydantoin derivatives were evaluated from the plasma concentrations after oral and intravenous administrations to dogs."( Biopharmaceutical studies on hydantoin derivatives. II. Pharmacokinetics and bioavailability of hydantoin derivatives in dogs.
Fujioka, H; Tan, T, 1982
)
0.26
"This study investigated the relative oral bioavailability of azimilide dihydrochloride following administration in the fed (high-fat meal) and fasted states."( Comparative oral bioavailability of azimilide dihydrochloride in the fed and fasted states.
Agnew, JR; Corey, AE; Nesbitt, JD; Powell, JH; Thompson, GA; Valentine, SN; Wagner, DL, 2000
)
0.31
" It is predicted that the high oral bioavailability for these compounds in multiple species should translate into lower intra- and intersubject variability in man."( Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Heath, JA; Hollenbach, SJ; Lambing, JL; Mehrotra, MM; Nannizzi-Alaimo, L; Pandey, A; Park, GL; Rose, JW; Scarborough, RM; Seroogy, JM; Smyth, MS; Volkots, DL, 2004
)
0.32
" The oral bioavailability of these antagonists was inversely correlated with polar surface area, suggesting that membrane permeability was a key limitation to absorption."( Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.
Bednar, RA; Bell, IM; Fay, JF; Gallicchio, SN; Graham, SL; Hochman, JH; Kane, SA; McMasters, DR; Miller-Stein, C; Moore, EL; Mosser, SD; Pudvah, NT; Quigley, AG; Salvatore, CA; Stump, CA; Theberge, CR; Vacca, JP; Williams, TM; Wong, BK; Zartman, CB; Zhang, XF, 2006
)
0.33
"Solid dispersions have been used as a strategy to improve the solubility, dissolution rate, and bioavailability of poor water-soluble drugs."( Solid dispersions of imidazolidinedione by PEG and PVP polymers with potential antischistosomal activities.
de Lima, Mdo C; de Oliveira, BG; De Simone, CA; Galdino, SL; Guedes, FL; Hernandes, MZ; Neto, PJ; Pitta, IR; Veiga, FJ, 2011
)
0.37
" It had lower oral absorption than salmeterol in rats, and lower bioavailability than salmeterol in vivo in both rats and dogs (2% and 5%, respectively)."( The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
Barrett, VJ; Bevan, NJ; Butchers, PR; Conroy, R; Emmons, A; Ford, AJ; Jeulin, S; Looker, BE; Lunniss, GE; Morrison, VS; Mutch, PJ; Perciaccante, R; Procopiou, PA; Ruston, M; Smith, CE; Somers, G, 2011
)
0.37
" (-)-18a has very good pharmacokinetic properties, including bioavailability in rat (F > 50%), and is currently under evaluation in phase I clinical trials."( Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
Alvey, L; Blanqué, R; Deprez, P; Feyen, J; Fletcher, S; Guédin, D; Hebbe, S; Housseman, C; Jary, H; Klaassen, H; Lefrançois, JM; Manioc, M; Minet, D; Namour, F; Nique, F; Peixoto, C; Robin-Jagerschmidt, C; Triballeau, N; Van Beeck, K; Van der Aar, E, 2012
)
0.38
" The compound was well absorbed (F% 98 in males and 76 in females), and showed low clearance in plasma (0."( ADME characterization in rats revealed immediate secretion of AZD7903 into the stomach after IV dosing.
Borg, N; Haglund, J, 2013
)
0.39
" The results show that generally, the investigated compounds attain good bioavailability properties."( In Silico Study of Chromatographic Lipophilicity Parameters of 3-(4-Substituted Benzyl)-5-Phenylhydantoins.
Keleman, S; Sekulic, TD; Tot, J; Tot, K; Trisovic, N; Uscumlic, G, 2016
)
0.65
" Evidently, this distal hydrophobic centre alters the bioavailability of the molecules."( Synthesis and Evaluation of Novel Diazaspiro Hydantoins as Potential Anticonvulsants.
Kumar, CSA; Mahadevaiah, KM; Prasad, SBB; Raj, CSA; Ramesha, KC; Veeresh, B, 2017
)
0.71
" In-vivo assay on HT-29 (human colorectal adenocarcinoma) animal xenograft model unveiled the significant anti-tumor efficacy along with oral bioavailability with maximum TGI 36% (i."( Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy.
Anisimova, NY; Choe, JY; Lavecchia, A; Loiodice, F; Meyer-Almes, FJ; Pokrovsky, VS; Ramaa, CS; Smirnova, GB; Sokolova, DV; Spirina, TS; Tilekar, K; Upadhyay, N, 2021
)
0.62
" A novel drug-like spirohydantoin (21) has been discovered as a selective orally bioavailable inhibitor of p300/CBP histone acetyltransferase."( Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases.
Algire, M; Bhat, V; Bromberg, KD; Clark, RF; Cole, PA; Jakob, CG; Ji, Z; Kesicki, EA; Lai, A; Lasko, LM; Liu, H; Manaves, V; Marmorstein, R; Martin, R; Matthew Hansen, T; Michaelides, MR; Qiu, W; Torrent, M, 2021
)
0.96

Dosage Studied

ExcerptRelevanceReference
"A simple, specific GLC procedure is described for the analysis of one sedative and six anticonvulsant drugs in pharmaceutical dosage forms."( Simple GLC analysis of anticonvulsant drugs in commercial dosage forms.
Lawrence, RC; Lovering, EG; Watson, JR, 1978
)
0.26
" Modification of the dosage scheme may be advisable."( Pre-anaesthetic administration of dantrolene sodium to a patient at risk from malignant hyperthermia: case report.
Free, CW; Jaimon, MP, 1978
)
0.26
" In all cases the results of the analysis of the drugs studied either in the pure state or in their dosage forms comply with those given by N-bromo succinimide (NBS) and by the official methods, however this application is distinguished by simplicity and accuracy."( Evaluation of certain pharmaceuticals with dibromodimethylhydantoin. Part 2: Determination of analgesics.
Abo-Ouf, A; Belal, F; Rizk, M; Walash, MI, 1979
)
0.26
" Four hours after dosing to rats and dogs, renal clearance of the ethyl-14C moiety (14--21%) is lower than that of the hydantoin-14C moiety (29--68%)."( The disposition of spirohydantoin mustard (NSC 172112) in rats and dogs.
Adamson, RH; Plowman, J, 1979
)
0.26
" Dose-response curves for exponentially growing and plateau-phase cells were similar and indicated that a small fraction of cells were resistant to SHM."( Response of 9L tumor cells in vitro to spirohydantoin mustard.
Bartle, PM; Deen, DF; Hoshino, T; Nomura, K; Williams, ME, 1979
)
0.26
" Combined treatment with other anticonvulsant drugs decreases the half-life and more frequent dosing may be necessary."( Clinical pharmacokinetics of anticonvulsants.
Dam, M; Hvidberg, EF, 1976
)
0.26
" Reduction in antiepileptic drug dosage should be carried out as a stepwise procedure over a period of about 2 years."( [A discussion of the curability of childhood epilepsies (author's transl)].
Groh, C, 1975
)
0.25
" Daily dosage of 300 mg or more is associated with higher incidenceof hepatotoxic reactions and with the majority (85%) of the fatalities."( Dantrolene-associated hepatic injury. Incidence and character.
Boitnott, JK; Utili, R; Zimmerman, HJ, 1977
)
0.26
" the dose-response curve on rat diaphragm was flatter."( The effects of dantrolene sodium on cardiac and skeletal muscle in rats.
Agoston, S; Meyler, MJ; Wesseling, H, 1976
)
0.26
" The best dosage schedule was individual and ranged from 50 mg to 300 mg a day."( [Clinical study of dantrolene sodium in the treatment of spastic and dystonic syndromes].
Baldassarre, L; Fraioli, B; Guglielmi, G,
)
0.13
" The dosage of dantrolene ranged from 100 mg per day initially to 600 mg per day maximally."( Effect of dantrolene sodium on spasticity associated with hemiplegia.
Ferguson, KL; Steinberg, FU, 1975
)
0.25
" Urine from a dog dosed orally at 20 mg/kg with 14C-imirestat, a spirohydantoin aldose reductase inhibitor, contained 17."( Application of 19F-n.m.r. spectroscopy to the identification of dog urinary metabolites of imirestat, a spirohydantoin aldose reductase inhibitor.
Gilbert, PJ; Hartley, TE; Troke, JA; Turcan, RG; Vose, CW; Watson, KV, 1992
)
0.28
" (3) The dosing regimen of the second study was repeated and, at two sampling times, nine tissues and plasma were obtained from four rats per sampling time for determination of imirestat tissue-to-plasma concentration ratio."( Saturable tissue binding and imirestat pharmacokinetics in rats.
Banfield, CR; Brazzell, RK; Chien, JY; Mayer, PR; Slattery, JT, 1992
)
0.28
" We report the elevated excretion of D-glucaric acid (DGA) and D-glucuronic acid (GCA) following treatment with 2,7-difluorospirofluorene-9,5'-imidazolidine-2'4'-dione (Imirestat, IM, Al 1576, HOE 843) at 50 mg/kg/day for 1 month, but not with 3-4-bromo-2-fluorobenzyl-4-oxo-3-phthalazine-1-ylacetic acid (Ponalrestat, Statil), dosed at 50 mg/kg/day for 2 weeks."( Studies on the biochemical effects of the aldose reductase inhibitor 2,7-difluorospirofluorene-9,5'-imidazolidine-2',4'-dione (Al 1576, HOE 843). Detection of D-glucaric and D-glucuronic acid excretion by high resolution 1H and 13C NMR spectroscopy.
Gilbert, PJ; Hoyle, VR; Nicholson, JK; Troke, JA; Vose, CW, 1992
)
0.28
") maternal serum concentrations of PHT, MPH, and ETH 1 hour after dosing on gestational day 18 were 16."( Comparison of the behavioral teratogenic potential of phenytoin, mephenytoin, ethotoin, and hydantoin in rats.
Acuff-Smith, KD; Minck, DR; Vorhees, CV, 1991
)
0.28
" During once-daily dosing of 2 to 20 mg/day for 4 weeks, mean steady-state imirestat concentration appeared to be dose proportional, although the time required to achieve steady state decreased with increasing dose."( Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.
Brazzell, RK; Dobbs, R; Mayer, PR; McNamara, PJ; Slattery, JT; Teng, RL, 1991
)
0.28
" The three ARIs (AL01567, AL01576, and AL01750) were administered intravenously as a single dose to all species except rat, which was dosed orally with AL01750, and man, who was dosed orally with AL01567 and AL01576."( Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.
Barker, R; Brazzell, RK; Couch, R; McCue, B; Park, YH; Wooldridge, CB; York, B,
)
0.13
" Imirestat was retained in the lens following topical dosing similar to that in cornea, with an apparent elimination t1/2 of 140 hr."( Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration.
Brazzell, RK; Hackett, RB; McCue, BA; Wooldridge, CB, 1990
)
0.28
"2 fold rightward shift of the dose-response curve."( Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C.
Hamid-Bloomfield, S; Whittle, BJ, 1989
)
0.28
" In the N3 nitrogen-substituted series one compound, 5,5-diphenyl-N3-n-butyl-2-thiohydantoin, DPBTH (7), showed promise during initial screening, but when analyzed in a dose-response study, its activity was considerably less than that of the parent compound DPTH."( 5,5-Diaryl-2-thiohydantoins and 5,5-diaryl-N3-substituted-2-thiohydantoins as potential hypolipidemic agents.
Tompkins, JE, 1986
)
0.61
" In contrast, PGD2 acted as a weak and partial inhibitor in guinea-pig platelet aggregation, producing a bell-shaped dose-response relationship."( Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.
Hamid, S; Whittle, BJ, 1985
)
0.27
"Two new potent aldose reductase inhibitors, AL-1567 (DL-spiro(2-fluoro-9H-fluoren-9,4'-imidazolidine)-2',5'-dione) and AL-1576 (spiro-(2,7-difluoro-9H-fluoren-9,4'-imidazolidine)2',5'-dione), have been characterized with respect to in vitro activity toward rat lens and human placental aldose reductase and in vivo activity in uncontrolled, severely diabetic rats dosed acutely with the compounds."( Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
Chandler, ML; Griffin, BW; McNatt, LG; York, BM, 1987
)
0.27
"A titrimetric method is described for the determination of three acetylenic hypnotics, namely ethchlorvynol, ethinamate, and methylpentynol carbamate, in bulk and in dosage forms."( Titrimetric determination of acetylenic hyponotics using organic brominating agents.
Belal, F; el-Brashy, A; Rizk, M; Walash, MI, 1988
)
0.27
" Injection of spiromustine on a split-dose schedule decreased the acute neurological toxicity in mice and allowed a larger total dosage to be delivered (compared to single bolus dosage)."( Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model.
Baker, LH; Corbett, T; Pazdur, R; Phillips, M; Redman, BG, 1987
)
0.27
"The simultaneous dosing of two drugs with co-regulated genetic polymorphisms determined by a single cytochrome P-450 isozyme could result in competitive inhibition of metabolism."( Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.
Branch, RA; Hall, SD; Jacqz, E; Wilkinson, GR, 1986
)
0.27
"05) shorter on BW245C at 1 h after dosing on each day."( Effect of a hydantoin prostaglandin analogue, BW245C, during oral dosing in man.
Al-Sinawi, LA; Burke, C; Hassan, S; Hedges, A; Mekki, QA; Moody, SG; O'Grady, J, 1985
)
0.27
" Plasma samples were collected for 49 hr after dosing and were assayed by HPLC for ethotoin."( Nonlinear ethotoin kinetics.
Burckart, GJ; Holcombe, BJ; Meyer, MC; Raghow, G; Yau, MK, 1983
)
0.27
"The ability of normal subjects to hydroxylate mephenytoin (100 mg) or debrisoquine (10 mg) after oral dosing was investigated in 156 unrelated Caucasians living in middle Tennessee."( Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Aslanian, WS; Branch, RA; McAllister, CB; Wedlund, PJ; Wilkinson, GR, 1984
)
0.27
" Heart rate, blood pressure and, using visual analogue scales, facial flushing, abdominal discomfort and headache, were measured before dosing, at 15 minute intervals after dosing for 2 hours and at 30 minute intervals for a further 2 hours."( Effects of single oral dose administration of a hydantoin prostaglandin analogue BW 245C in man.
Joshi, M; O'Grady, J; Pickles, H; Shah, A; Webster, A, 1984
)
0.27
"-mass spectrometric analysis of urine extracts from rats dosed with tocainide (I) revealed the presence of cyclic compound identified as 3-(2,6-xylyl)-5-methylhydantoin (IV) derived from tocainide."( 3-(2,6-Xylyl)-5-methylhydantoin--a metabolite or a metabonate of tocainide in rats.
Axelson, JE; Venkataramanan, R, 1981
)
0.26
" A cross-sectional analysis of items such as designs, patient sampling principles, recording of effect parameters and side effects, concomitant treatments, and statistical evaluations demonstrated that cross-over designs, investigating fixed dosage schedules, were extensively used."( Controlled trials in epilepsy: a review.
Bentsen, KD; Flachs, H; Gram, L; Parnas, J, 1982
)
0.26
" The towers were dosed with these biocides for approximately 4 weeks."( Field trial of biocides for control of Legionella in cooling towers.
Bentham, RH; Broadbent, CR, 1995
)
0.29
"A titrimetric method, with N,N-dibromodimethylhydantoin as reagent, has been developed for the determination of cimetidine in pure form and in dosage forms."( Determination of cimetidine in pure form and in dosage forms using N,N-dibromodimethylhydantoin.
Karpagaselvi, L; Kumar, KG, 1994
)
0.29
" Rats dosed orally (100 mg/kg) were fully protected from VF."( Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
Brooks, RR; Carpenter, JF; Maynard, AE; Miller, KE, 1996
)
0.29
" Clearly, ocular dosing with AL-4114 and AL-1576 for 14 days had little effect on hepatic, intestinal, and ocular biotransformation."( Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
Sanders, RA; Sastry, SG; Veltman, JC; Watkins, JB, 1995
)
0.29
" It was found that at the same dosage of 10 mg/kg/day, both AL01576 and AL04114 completely prevented all morphological and biochemical changes in the lenses of naphthalene-fed rats."( Inhibition of naphthalene cataract in rats by aldose reductase inhibitors.
Lou, MF; Xu, GT; York, B; Zigler, S, 1996
)
0.29
" Dosing adjustments based on either age or gender are not required."( Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride.
Agnew, J; Bao, J; Bryson, P; Comer, P; Corey, A; Griffith, S; Li, J, 1997
)
0.3
" Animals were dosed topically with 'test article'--neat HD, 10% agent/chloroform solutions or product solutions (waste-streams) from neutralized CAIS--and evaluated for skin-damaging effects (gross and microscopic)."( Evaluation of neutralized chemical agent identification sets (CAIS) for skin injury with an overview of the vesicant potential of agent degradation products.
Hayes, TL; MacIver, B; Menton, RG; Miller, TL; Olajos, EJ; Olson, CT; Rosso, T; Salem, H; Singer, AW,
)
0.13
" Male offsprings display a higher incidence of epididymal and testicular lesions than generally seen with flutamide, P, or V even at high dosage levels."( Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p'-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differen
Cooper, RL; Gray, LE; Lambright, C; Mann, P; Ostby, J; Price, M; Wolf, C,
)
0.13
" At a dosage of 125 mg once daily, azimilide significantly increased the time to first symptomatic recurrence of atrial fibrillation/flutter."( Azimilide.
Clemett, D; Markham, A, 2000
)
0.31
" Compound 11a also potentiated the effects of L-DOPA in a rat model of Parkinson's disease (the 6-hydroxydopamine-lesioned rat), dosed at 30 mg/kg orally."( Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.
Meltzer, LT; Schelkun, RM; Serpa, K; Whittemore, ER; Wise, LD; Woodward, RM; Yuen, PW, 2000
)
0.31
" Patients received oral azimilide (100 mg in SVA-1 and SVA-3, 35 or 75 mg in SVA-2, and 125 mg in SVA-4) or matching placebo twice daily for 3 days (loading period), followed by once-daily dosing (maintenance period)."( Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
Connolly, SJ; Marcello, SR; Page, RL; Pritchett, EL; Schnell, DJ; Wilkinson, WE, 2002
)
0.31
" U-46619 evoked a sharp decrease in microvessel diameter within a 10(-7)-10(-4)M gamut, with the dose-response profiles at 5- and 10-min timepoints remaining essentially parallel over the tested range of concentrations."( Vascular activities of prostaglandins and selective prostanoid receptor agonists in human retinal microvessels.
Nieves, AL; Spada, CS; Woodward, DF, 2002
)
0.31
"Since azimilide blood concentrations are essentially unaffected by renal function, an a priori dosage regimen adjustment is not required in patients with renal impairment."( Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration.
Agnew, JR; Corey, AE; Parekh, NJ; Powell, JH; Thompson, GA; Valentine, SN, 2002
)
0.31
" Based on these results, no a priori dosage adjustment is required in subjects with mild to moderate hepatic impairment."( Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration.
Agnew, JR; Corey, AE; King, EC; Parekh, NJ; Powell, JH; Thompson, GA, 2004
)
0.32
" The complexity of these dose-response relationships is likely due to the dual role of peroxynitrite as both an oxidant and a nucleophile in competition with water."( Quantitation of four guanine oxidation products from reaction of DNA with varying doses of peroxynitrite.
Tannenbaum, SR; Venkatarangan, L; Wishnok, JS; Yu, H, 2005
)
0.33
" After oral dosing in a rat atrophied levator ani muscle model, (7R,7aS)-10b demonstrated efficacy at restoring levator ani muscle mass to that of intact controls and exhibited >50-fold selectivity for muscle over prostate."( Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
An, Y; Beehler, BC; Fura, A; Golla, R; Grover, GJ; Hamann, LG; Huang, Y; Krystek, SR; Kuhns, JE; Lupisella, JA; Malley, MF; Ostrowski, J; Robl, JA; Sack, JS; Salvati, ME; Seethala, R; Sleph, PG; Sun, C; Wang, TC, 2006
)
0.33
" Sprague-Dawley weanling rats were dosed by gavage with 0, 50, 100, or 200mg/kg/day of IPRO from post-natal day (PND) 23 to 51/52."( Iprodione delays male rat pubertal development, reduces serum testosterone levels, and decreases ex vivo testicular testosterone production.
Blystone, CR; Furr, J; Gray, LE; Lambright, CS; Wilson, VS, 2007
)
0.34
" The MN response depended on the sampling time and the concentration used, which showed a significant dose-response correlation (r=0."( Genotoxic effects of the pesticides Rubigan, Omite and Rovral in root-meristem cells of Crepis capillaris L.
Dimitrov, B; Gadeva, P, 2008
)
0.35
" Sprague-Dawley rats were dosed by gavage with vinclozolin at 0, 10, 30, 60, and 100 mg/kg/day with and without 50 mg iprodione/kg/day from postnatal day (PND) 23 to 55-57 (n = 8 per group)."( Cumulative and antagonistic effects of a mixture of the antiandrogens vinclozolin and iprodione in the pubertal male rat.
Blystone, CR; Cardon, MC; Furr, J; Gray, LE; Hartig, PC; Lambright, CS; Rider, CV; Wilson, VS, 2009
)
0.35
" An improved method for measuring the absorbed fraction of analogues dosed to rats, which considers the glucuronidated fraction is presented."( The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
Barrett, VJ; Bevan, NJ; Butchers, PR; Conroy, R; Emmons, A; Ford, AJ; Jeulin, S; Looker, BE; Lunniss, GE; Morrison, VS; Mutch, PJ; Perciaccante, R; Procopiou, PA; Ruston, M; Smith, CE; Somers, G, 2011
)
0.37
" In a standard castrated male rat model, several compounds showed good anabolic activity on levator ani muscle, dissociated from the androgenic activity on ventral prostate, after oral dosing at 30 mg/kg."( Discovery of diarylhydantoins as new selective androgen receptor modulators.
Annoot, D; Clément-Lacroix, P; Deprez, P; Duval, E; Fleury, D; Guédin, D; Hebbe, S; Lefrançois, JM; Lemoullec, JM; Michoux, L; Minet, D; Mollat, P; Nique, F; Peixoto, C; Prangé, T; Robin-Jagerschmidt, C; Thauvin, M; Triballeau, N, 2012
)
0.71
" In this study, we have examined the dose-response relationship for the formation of the above four products arising in calf thymus DNA exposed to gamma irradiation, photoactivated rose bengal, and two sources of peroxynitrite."( Comparative analysis of four oxidized guanine lesions from reactions of DNA with peroxynitrite, singlet oxygen, and γ-radiation.
Cui, L; Dedon, PC; Prestwich, EG; Taghizadeh, K; Tannenbaum, SR; Wishnok, JS; Ye, W, 2013
)
0.39
" dosage in rats."( ADME characterization in rats revealed immediate secretion of AZD7903 into the stomach after IV dosing.
Borg, N; Haglund, J, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Cococare Shea Butter Cream -- 15 ozCococareBeauty & Personal Carecetyl alcohol, EDTA, hydantoin, methylparaben, propylparaben, stearic acid2024-11-29 10:47:42

Drug Classes (1)

ClassDescription
imidazolidine-2,4-dioneAn imidazolidinone with oxo groups at position 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase betaHomo sapiens (human)Potency63.09570.022421.010289.1251AID485314
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glycogen synthase kinase-3 alphaHomo sapiens (human)IC50 (µMol)100.00000.00101.22499.1000AID282721
Glycogen synthase kinase-3 betaHomo sapiens (human)IC50 (µMol)100.00000.00060.801310.0000AID282721
Protein cereblonHomo sapiens (human)IC50 (µMol)421.00000.28601.70663.0000AID1685005
Protein cereblonHomo sapiens (human)Ki216.00001.49006.580010.0000AID1685005
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.06200.00030.70285.3660AID204286
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (105)

Processvia Protein(s)Taxonomy
regulation of systemic arterial blood pressureGlycogen synthase kinase-3 alphaHomo sapiens (human)
cardiac left ventricle morphogenesisGlycogen synthase kinase-3 alphaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
nervous system developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of UDP-glucose catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell migrationGlycogen synthase kinase-3 alphaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to insulin stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of heart contractionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glucose importGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to lithium ionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to glucocorticoid stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
autosome genomic imprintingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of mitophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of amyloid-beta formationGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein targeting to mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphateGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
ER overload responseGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of apoptotic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
epithelial to mesenchymal transitionGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell-matrix adhesionGlycogen synthase kinase-3 betaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrion organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 betaHomo sapiens (human)
hippocampus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
establishment of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
maintenance of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of cell migrationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axon extensionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of phosphoprotein phosphatase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule-based processGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 betaHomo sapiens (human)
regulation of circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of GTPase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of osteoblast differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cilium assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein autophosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of dendrite morphogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axonogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeGlycogen synthase kinase-3 betaHomo sapiens (human)
superior temporal gyrus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to retinoic acidGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 betaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule anchoring at centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of cellular response to heatGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein localization to nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of long-term synaptic potentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein acetylationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to ciliumGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to amyloid-betaGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complex disassemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of mesenchymal stem cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
signaling receptor bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protease bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
p53 bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ubiquitin protein ligase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
dynactin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
NF-kappaB bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 alphaHomo sapiens (human)
neuronal cell bodyGlycogen synthase kinase-3 alphaHomo sapiens (human)
apical dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 alphaHomo sapiens (human)
proximal dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 alphaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 alphaHomo sapiens (human)
axonGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
glutamatergic synapseGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 betaHomo sapiens (human)
centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
dendriteGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 betaHomo sapiens (human)
presynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
Wnt signalosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID282721Inhibition of rabbit GSK32005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID648277Inhibition of Dengue virus NS2B-NS3 protease using Abz-NleKRRS-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins measured every sec for 15 mins by fluorimetric analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
AID648278Inhibition of bovine plasma thrombin using Boc-Val-Pro-Arg-AMC as substrate at 25 uM preincubated for 15 mins measured after 10 mins by fluorimetric assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
AID204286Inhibitory activity towards Sigma opioid receptor type 11999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Mixture-based synthetic combinatorial libraries.
AID1685005Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence by MST based assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1649763Binding affinity to 15N-labeled FKBP51 (1 to 140 residues) (unknown origin) expressed in Escherichia coli OD2N assessed as induction of chemical shift perturbations by two-dimensional 1H/15N HSQC NMR spectroscopy2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
AID648279Inhibition of Escherichia coli MurA using PEP as substrate assessed as inorganic phosphate release at 25 uM preincubated for 10 mins measured after 60 mins by fluorimetric assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
AID648280Inhibition of Escherichia coli MetAP at 10 uM after 15 mins by fluorescence analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,197)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902029 (63.47)18.7374
1990's257 (8.04)18.2507
2000's422 (13.20)29.6817
2010's400 (12.51)24.3611
2020's89 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.86 (24.57)
Research Supply Index8.16 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index107.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials80 (2.35%)5.53%
Reviews129 (3.79%)6.00%
Case Studies92 (2.70%)4.05%
Observational1 (0.03%)0.25%
Other3,102 (91.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]